Sitagliptin phosphate and Ranitidine drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Sitagliptin phosphate (sitagliptin phosphate) and Ranitidine (ranitidine). Common drug interactions include toxic epidermal necrolysis among females and deep vein thrombosis among males.

The phase IV clinical study analyzes what interactions people have when they take Sitagliptin phosphate and Ranitidine. It is created by eHealthMe based on reports of 41 people who take the same drugs from the FDA, and is updated regularly.

What is Sitagliptin phosphate?

Sitagliptin phosphate has active ingredients of sitagliptin phosphate. eHealthMe is studying from 3,787 Sitagliptin phosphate users. Check the latest studies of Sitagliptin phosphate.

What is Ranitidine?

Ranitidine has active ingredients of ranitidine. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 234,475 Ranitidine users. Check the latest studies of Ranitidine.



On Jul, 06, 2026

41 people who take Sitagliptin phosphate and Ranitidine together, and have interactions are studied.

Sitagliptin phosphate and Ranitidine drug interactions.

What are the common drug interactions of Sitagliptin Phosphate and Ranitidine, by gender? *:

female:

  1. Toxic epidermal necrolysis (a rare, life-threatening skin condition that is usually caused by a reaction to drugs causes wide spread skin destruction)
  2. Type 2 diabetes mellitus
  3. Upper respiratory tract infection
  4. Urticaria (rash of round, red welts on the skin that itch intensely)
  5. Weight decreased
  6. Wheezing (a high-pitched whistling sound made while you breath)
  7. Accidental exposure
  8. Accidental needle stick
  9. Bronchospasm (spasm of bronchial smooth muscle producing narrowing of the bronchi)
  10. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)

male:

  1. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  2. Pulmonary embolism (blockage of the main artery of the lung)
  3. Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures)
  4. Erythema (redness of the skin)
  5. Fibrosis (formation of excess fibrous connective tissue in an organ or tissue)
  6. Haemorrhagic anaemia (anaemia due to excessive bleeding)
  7. Hot flush (sudden feelings of heat)
  8. Hypersensitivity
  9. Hypotension (abnormally low blood pressure)
  10. Interstitial lung disease

What are the common drug interactions of Sitagliptin Phosphate and Ranitidine, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Hot flush (sudden feelings of heat)
  2. Pruritus (severe itching of the skin)
  3. Swelling face

40-49:

  1. Hypoaesthesia (reduced sense of touch or sensation)
  2. Hypochromic anaemia (hypochromic anaemia is a generic term for any type of anaemia in which the red blood cells (erythrocytes) are paler than normal)
  3. Iron deficiency anaemia
  4. Muscle spasms (muscle contraction)
  5. Nasal congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels)
  6. Nasal dryness (dry nose)
  7. Nausea (feeling of having an urge to vomit)
  8. Nephrolithiasis (calculi in the kidneys)
  9. Obesity (having too much body fat)
  10. Pain

50-59:

  1. Anaemia (lack of blood)
  2. Diarrhoea
  3. Tachycardia (a heart rate that exceeds the range of 100 beats/min)
  4. Abdominal pain
  5. Anuria (failure of the kidneys to produce urine)
  6. Cerebral haemorrhage (bleeding within the brain)
  7. Febrile neutropenia (fever with reduced white blood cells)
  8. Malaise (a feeling of general discomfort or uneasiness)
  9. Pneumonia
  10. Respiratory failure (inadequate gas exchange by the respiratory system)

60+:

  1. Hypertension (high blood pressure)
  2. Contusion (a type of hematoma of tissue in which capillaries)
  3. Exercise tolerance decreased
  4. Mobility decreased (ability to move is reduced)
  5. Oedema peripheral (superficial swelling)
  6. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  7. Pulmonary embolism (blockage of the main artery of the lung)
  8. Lacunar infarction (a type of stroke)
  9. Renal failure acute (rapid kidney dysfunction)
  10. Subdural haematoma (blood collects between the skull and the surface of the brain)

What are the existing conditions these people have? *

  1. Diabetes: 13 people, 31.71%
  2. High Blood Pressure: 11 people, 26.83%
  3. Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 9 people, 21.95%
  4. Pain: 9 people, 21.95%
  5. Indigestion: 7 people, 17.07%
  6. Restless Leg Syndrome (a powerful urge to move your legs): 6 people, 14.63%
  7. Psoriasis (immune-mediated disease that affects the skin): 6 people, 14.63%
  8. Osteoporosis (bones weak and more likely to break): 6 people, 14.63%
  9. Oedema Peripheral (superficial swelling): 6 people, 14.63%
  10. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 6 people, 14.63%

* Approximation only. Some reports may have incomplete information.

Do you take Sitagliptin phosphate and Ranitidine?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Sitagliptin phosphate and Ranitidine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Sitagliptin phosphate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Ranitidine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Sitagliptin phosphate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ranitidine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on sitagliptin phosphate and ranitidine (the active ingredients of Sitagliptin phosphate and Ranitidine, respectively), and Sitagliptin phosphate and Ranitidine (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: